Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Aldeyra Therapeu (ALDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 200,684
  • Shares Outstanding, K 27,491
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,890 K
  • 60-Month Beta 0.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.51
  • Number of Estimates 2
  • High Estimate -0.39
  • Low Estimate -0.63
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -10.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.10 +0.28%
on 05/20/19
8.47 -15.94%
on 04/29/19
-0.64 (-8.25%)
since 04/18/19
3-Month
6.81 +4.55%
on 03/25/19
12.79 -44.33%
on 03/26/19
-0.63 (-8.13%)
since 02/20/19
52-Week
6.75 +5.48%
on 08/06/18
16.70 -57.37%
on 09/26/18
-1.68 (-19.09%)
since 05/18/18

Most Recent Stories

More News
Aldeyra Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases,...

ALDX : 7.12 (-2.47%)
Aldeyra Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases,...

ALDX : 7.12 (-2.47%)
Aldeyra Therapeutics Announces Last Patient Dosed in the SOLACE Phase 3 Clinical Trial

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases,...

ALDX : 7.12 (-2.47%)
Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases,...

ALDX : 7.12 (-2.47%)
Recent Analysis Shows Flowserve, Pinnacle West Capital, Aldeyra Therapeutics, Donnelley Financial Solutions, NIC, and Enphase Energy Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Flowserve Corporation (NYSE:FLS),...

ALDX : 7.12 (-2.47%)
ENPH : 14.31 (-2.32%)
PNW : 96.59 (+0.55%)
DFIN : 13.57 (-0.73%)
EGOV : 16.19 (-1.22%)
FLS : 49.60 (+0.24%)
Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases,...

ALDX : 7.12 (-2.47%)
Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge

Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.

ALDX : 7.12 (-2.47%)
AZN : 37.54 (-0.64%)
RHHBY : 33.1100 (+0.82%)
BHC : 24.23 (-3.31%)
Medical Device Industry Revenues Should Outpace Healthcare Field

The U.S. markets are bullish on the future of the medical device markets. In addition to projections that postulate that: "In 2024, the total medical technology revenue globally is expected be nearly $600...

ALDX : 7.12 (-2.47%)
MHMNF : 54.5000 (unch)
ENDP : 6.24 (-4.29%)
ABBV : 79.82 (+0.45%)
BPTH : 15.02 (-3.28%)
SOLY : 6.41 (-12.43%)
Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases,...

ALDX : 7.12 (-2.47%)
Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases,...

ALDX : 7.12 (-2.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade ALDX with:

Business Summary

Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 7.29
1st Resistance Point 7.21
Last Price 7.12
1st Support Level 7.07
2nd Support Level 7.01

See More

52-Week High 16.70
Fibonacci 61.8% 12.90
Fibonacci 50% 11.73
Fibonacci 38.2% 10.55
Last Price 7.12
52-Week Low 6.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar